JTO Clinical and Research Reports (Nov 2021)

Malignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report

  • Helen Ke, MBBS (Hons),
  • Anthony J. Gill, AM, MBBS, FRCPA,
  • Catriona McKenzie, MBBS (Hons1), FRCPA,
  • James G. Kench, MBBS, Bsc(Med), FRCPA,
  • Renee C.F. Chan, MBBS(Hons1), FRCPA,
  • Nick Pavlakis, BSc, MBBS, MMed(Clin. Epi), PhD, FRACP,
  • Michael Fulham, MBBS(Hons), FRACP,
  • Cherry Koh, MBBS (Hons), MS, FRACS,
  • Steven Kao, BHB, MBChB, PhD, FRACP

Journal volume & issue
Vol. 2, no. 11
p. 100236

Abstract

Read online

Malignant mesothelioma with EWSR1-ATF1 fusion is a rare malignancy described in young adults without asbestos exposure. To the best of our knowledge, outcomes to local and systemic therapies for this subtype of malignant mesothelioma have not been described. This case report describes the clinical course of a 19-year-old man diagnosed with malignant peritoneal mesothelioma with EWSR1-ATF1 fusion localized to the abdomen. His disease followed an aggressive course and resulted in limited survival (18 mo). There was treatment resistance to several lines of conventional local and systemic treatments for peritoneal mesothelioma and biologically targeted MET inhibition with crizotinib. More research is required in this rare subtype of peritoneal mesothelioma.

Keywords